Editor’s showcase: Ranking the most fresh COVID-19 files and guidance in Medscape’s Coronavirus Resource Heart.
Use of mRNA COVID-19 vaccines desires to be regarded as because the preferable option in the US instead of Johnson & Johnson’s (J&J) Janssen COVID-19 vaccine in girls below the age of 50 years, basically basically based on one crew of experts.
The crew makes their advice in an editorial in JAMA printed online April 30, accompanying a paper describing essential factors of 12 case reports of cerebral venous sinus thrombosis (CVST) with thrombocytopenia following the J&J COVID-19 vaccine, also identified because the Advert26.COV2.S vaccine.
The editorialists are Ruth A. Karron, MD, professor of worldwide health at Johns Hopkins Bloomberg Faculty of Public Health in Baltimore, Maryland; Nigel S. Key, MD, professor of hematology at University of North Carolina at Chapel Hill; and Joshua M. Sharfstein, MD, companion dean for public health put together at Johns Hopkins Bloomberg Faculty of Public Health.
They showcase that after an preliminary quit following reports of thrombosis with thrombocytopenia syndrome (TTS) linked to the J&J vaccine, and on the advice of the Advisory Committee on Immunization Practices, the US has permitted the utilization of the J&J vaccine in all adults with knowledge on the probability of TTS added to tutorial affords.
The editorialists point out that no cases of TTS had been confirmed following administration of more than 180 million doses of the mRNA vaccines in the US.
They pronounce that while the J&J vaccine will quiet be wished for folks with allergic reactions to factors of the mRNA vaccines and for folks that live in distant locations the place the chilly chain for transport and storage of mRNA vaccines can no longer be maintained, “US public health companies and clinicians must withhold in mind recommending mRNA vaccines as safer alternate recommendations for folks that will seemingly be at considerably bigger probability for TTS after Advert26.COV2.S vaccination, at point to ladies youthful than 50 years.”
In the most essential JAMA paper, a crew led by Isaac Ogle, MD, Facilities for Illness Administration and Prevention (CDC) COVID-19 Response Group, document paunchy essential factors of 12 cases of CVST with thrombocytopenia following the J&J COVID-19 vaccine reported to the US Vaccine Hostile Occasion Reporting Machine (VAERS).
The 12 US case reports, three of which had been fatal, explain many similarities to cases described in Europe after the AstraZeneca vaccine.
The authors showcase that by April 12, roughly 7 million doses of the J&J vaccine had been given in the US. The 12 cases of CVST and thrombocytopenia following receipt of the vaccine had been reported to VAERS between March 2 and April 21. All 12 cases had been in white girls, 11 of whom had been below 50 years of age.
As of April 25, an additional two cases had been confirmed and reported to VAERS; one in a particular person youthful than 40 years, the opposite in a lady worn between 40 and 59 years.
In the 12 cases reported in part, symptoms began between 6 and 15 days post vaccination.
As a minimum 1 probability part for CVST was once diagnosed in 7 patients (obesity in 6, hypothyroidism in 1, and spend of blended oral contraceptives in 1). No longer one in every of the patients was once pregnant or interior 12 weeks postpartum, had prior thrombosis, a non-public or family historical previous of thrombophilia, or documented prior exposure to heparin.
Besides to CVST, seven patients had intracerebral hemorrhage and eight had non-CVST thromboses.
One patient reported a historical previous of SARS-CoV-2 infection roughly 4 months outdated to vaccination. Of the opposite 11 patients, four had antagonistic serologic exams and 7 had been no longer tested.
All 12 patients had been hospitalized and 10 had been admitted to an intensive care unit (ICU). At the time of the final put together-up, three patients had died (all of whom had intraparenchymal hemorrhage), three remained in the ICU, two had been quiet hospitalized but no longer in an ICU, and 4 had been discharged home.
The authors point out that the US cases of CVST with thrombocytopenia following the J&J vaccine contain many similarities to those reported in Europe after the AstraZeneca vaccine, taking place basically in girls youthful than 40 years and in patients without identified thrombophilia. Both European and US patients had a median platelet nadir rely of 19×103/µL and plenty of different also had non-CVST astronomical-vessel thrombosis.
In the European cases of CVST with thrombocytopenia, 50% of patients died, when in contrast with 25% of US patients.
Love the European cases, the US cases had obvious heparin-PF4 HIT antibody ELISA exams in the absence of prior exposure to heparin, as would be seen in autoimmune HIT.
On the other hand, in the preliminary European CVST reports, 88% of patients tested with purposeful platelet HIT antibody exams had obvious outcomes, when in contrast with fully 11% of the US cases. However the authors showcase that lack of standardization in purposeful platelet HIT antibody assays could well also consequence in differences in outcomes by totally different laboratories.
“It would be essential to explain sorting out laboratories that post-vaccination TTS is being evaluated, so that sorting out ideas will seemingly be adjusted if wished,” they pronounce.
They terminate that these case reports point out that the pathogenesis of TTS will seemingly be identical to autoimmune HIT, introduced on by the formation of antibodies directed in opposition to PF4, a constituent of platelet alpha granules launched all over platelet activation. In distinction to traditional HIT in which exogenous heparin triggers antibody formation, in autoimmune HIT, an endogenous polyanion triggers PF4 antibody formation.
They showcase that the particular mechanism of TTS in relation to COVID-19 vaccination has no longer yet been established. The World Advisory Committee on Vaccine Security has mentioned that a platform-advise mechanism connected to adenovirus vector vaccines can no longer be excluded. Both the J&J and AstraZeneca vaccines spend an adenoviral vector, but they’re totally different; J&J uses a human vector, while AstraZeneca uses a chimpanzee vector.
Besides they point out that CVST and thrombocytopenia following SARS-CoV-2 infection has been reported in no much less than two cases, but HIT sorting out was once no longer done in these cases. There contain no longer to this point been any reports to VAERS of CVST with thrombocytopenia following mRNA COVID-19 vaccines.
The authors pronounce these findings contain essential medical and public health implications, noting that the CDC has updated its interim medical considerations to be used of authorized COVID-19 vaccines to showcase that girls worn 18 to 49 years desires to be attentive to the increased probability of TTS after receipt of the J&J vaccine, and to spend a nonheparin anticoagulant in suspected cases.
They showcase that a subacute presentation of headache is fresh in 90% of patients with long-established CVST. Whereas headache is a frequent symptom after the J&J vaccination, most complications initiate and resolve interior two days. Whereas in the US cases of CVST after vaccination, headache symptoms began no much less than six days after vaccination and endured for as a minimum a week for most.
“Pressing consultation with a neurologist is prudent when a patient is suspected or confirmed to contain CVST. Besides, since the median time from symptom onset to hospitalization was once seven days in the US CVST case series, patient and clinician education could well also shorten the time to medical review and therefore treatment,” they direct.
The authors also showcase that VAERS is a passive surveillance system, so cases of CVST with thrombocytopenia will seemingly be underreported.
Of their accompanying editorial, Karron et al point out that to boot to to the 12 patients with CVST with thrombocytopenia described in this case series, no much less than three patients without CVST but assembly diagnostic criteria for TTS had been reported to VAERS (as of April 21), all in girls worn 18 to 59 years (median age, 37 years).
The editorialists document that the rate of CVST with thrombocytopenia after the J&J vaccine is roughly 5 per million girls worn 18 to 50 years. This is when in contrast with a background rate of roughly 0.05 to 0.13 per million per month.
They pronounce that the provision of an interim standardized case definition of this damaging enact will facilitate prospective case ascertainment thru review of astronomical linked databases and lively case finding.
This can even additionally enable increased working out of whether contributors who are otherwise at increased probability for hypercoagulation in long-established and for CVST in advise (as an illustration, girls taking hormonal contraceptive drugs or who are pregnant) are also at increased probability for TTS.
Acquiring this knowledge will enhance dynamic nation-advise assessments of the dangers of every vaccine when in contrast with the probability of COVID-19 disease for their populations and subpopulations, they add.